SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 📊Experiments 🤖Agents 🚦Status 📑Docs

Info

ℹVision ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

Vision Showcase Demo

Home / Wiki / Clinical: Noradrenergic Arousal System Phase 3 PD Trial (NCT07316296)

clinical 2,493 words KG: PD

kind:clinical-trial section:clinical-trials topic:parkinsons state:published

Contents

Noradrenergic Arousal System Phase 3 PD Trial (NCT07316296)

Knowledge Graph

Related Hypotheses (14)

PARP1 Inhibition Therapy
Score: 0.58 Blood-Brain Barrier SPM Shuttle System
Score: 0.56 Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54 Phase-Separated Organelle Targeting
Score: 0.52 Noradrenergic-Tau Propagation Blockade
Score: 0.51

Stress Granule Phase Separation Modulators
Score: 0.49 Lysosomal Calcium Channel Modulation Therapy
Score: 0.49 Lysosomal Enzyme Trafficking Correction
Score: 0.49 Arginine Methylation Enhancement Therapy
Score: 0.46 Lysosomal Membrane Repair Enhancement
Score: 0.45 Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45 Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44 Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.43 Mitochondrial Calcium Buffering Enhancement via MCU Modulati
Score: 0.38

Related Analyses (8)

Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived

RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed

Related Experiments (2)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40 Cytochrome Therapeutics
clinical · proposed · Score: 0.40

See Also (11)

LRRK2 G2019S Transgenic Mouse Model
model · KG edge: causes Age-Sensitive Cortical Vulnerability in Parkinson's Dis
mechanism · KG edge: associated_with MCL1 Gene - Myeloid Cell Leukemia 1
gene · KG edge: implicated_in IDH1 Gene - Isocitrate Dehydrogenase 1
gene · KG edge: implicated_in eef1a1
gene · KG edge: implicated_in

DOT1L Gene
gene · KG edge: implicated_in CNTNAP4 Gene
gene · KG edge: associated_with APOB Gene
gene · KG edge: implicated_in ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member
gene · KG edge: implicated_in DNA Damage Repair Deficiency Validation Study in Parkin
experiment · KG edge: implicated_in GBA1 (Redirect)
redirect · KG edge: causes

Knowledge Graph (12 edges)

PD causes NEURODEGENERATION

PD causes DOPAMINERGIC_NEURONS

PD causes neurodegeneration

PD contributes_to synucleinopathies

PD associated_with DEPRESSION

PD associated_with T2DM

NEUROINFLAMMATION contributes_to PD

NEUROTROPHINS treats PD

AGE associated_with PD

SNCA causes PD

SciDEX — scidex.ai — Dashboard | Atlas